Pacira Biosciences, Inc. (PCRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 26, 2024, by Pacira Biosciences, Inc., a Delaware corporation. The filing primarily addresses two material events: the announcement of financial results for the fourth quarter and full year ended December 31, 2023, and the departure of the Company's Chief Financial Officer.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the fourth quarter and full year ended December 31, 2023. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Corporate Events
The most significant material change disclosed in this filing is the departure of Charles A. Reinhart, III, the Company's Chief Financial Officer. Mr. Reinhart will depart effective September 30, 2024. The Company has commenced a search for a successor.
In connection with his departure, Mr. Reinhart will receive the following compensation and benefits:
- Continued base salary for nine months following the transition date.
- Eligibility for a pro-rated 2024 short-term cash bonus.
- Eligibility for a 2021 long-term incentive cash bonus upon completion of the vesting period.
- Eligibility for a 2024 annual equity grant (planned at 25% of intended value) with a one-year cliff-vesting schedule.
- Immediate vesting of unvested stock options and restricted stock units that would have vested during the nine-month post-transition period.
- Extended exercise period for vested stock options (lesser of stated term or three months post-service).
- Continued health benefits for 12 months following the transition date.
Additionally, Mr. Reinhart will enter into a Consulting Agreement effective October 1, 2024, providing transition services until June 30, 2025.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a detailed discussion of risks beyond the standard disclosure regarding the CFO transition. The financial outlook is referenced only by the existence of the press release issued on February 29, 2024.
Key Facts for Investor Verification
- Verify the specific Q4 and full-year 2023 financial results (revenue, net income, cash flow) in the press release dated February 29, 2024 (Exhibit 99.1), as they are not detailed in this 8-K text.
- Confirm the timeline for the CFO search and the appointment of an interim or permanent successor.
- Review the specific conditions attached to Mr. Reinhart's bonus and equity vesting to understand potential future cash outflows.
- Monitor the transition period from October 1, 2024, to June 30, 2025, during which Mr. Reinhart will serve as a consultant.